Weekly · World Stock Push
A new review found that GLP-1 drugs may improve obstructive sleep apnea (OSA) related to obesity. The effects of tirzepatide (Zepbound), FDA-approved for OSA, were especially notable. GLP-1s improve OSA by promoting fat loss in the neck, throat, and tongue.
CPAP therapy should continue until a physician confirms remission via a sleep study. GLP-1 medications like Zepbound and Wegovy show promise in easing sleep apnea symptoms. Published in JAMA Otolaryngology on September 3, the review highlights that GLP-1 receptor agonists significantly improve OSA in obesity.
Tirzepatide (Zepbound, Mounjaro) also affects glucose-dependent insulinotropic polypeptide (GIP) receptors. Zepbound is FDA-approved for OSA treatment. OSA occurs when throat muscles relax, blocking the airway.
While CPAP is standard treatment, weight loss reduces neck and tongue fat, keeping the airway open. The review found that tirzepatide reduced apnea-hypopnea index (AHI) by 20–24 events/hour, with up to 50% achieving full remission. However, CPAP remains superior.
The research team examined studies from 2016–2025, focusing on GLP-1s, AHI, and neuromuscular function. The primary mechanism is weight loss, reducing neck fat and improving airway openness. Losing 10% body weight linked to a 26% AHI reduction.
Emerging research suggests GLP-1s may stabilize breathing by altering respiratory control. They also improve leptin signaling, supporting airway muscles. GLP-1s have anti-inflammatory effects, protecting airway muscles from oxygen drops.
Clinical trials showed tirzepatide reduced AHI by 20–24 events/hour, with 42–50% achieving remission. Liraglutide also improved AHI and weight loss in the SCALE Sleep Apnea trial. While GLP-1s are not a cure, they may supplement CPAP for patients who cannot tolerate it or need weight loss before surgery.
Long-term benefits, effects on non-obese patients, and cardiovascular risks remain unclear. Experts emphasize combining GLP-1s with other therapies like Inspire therapy for anatomical issues. Patients should continue CPAP and repeat sleep studies after 12 months.
Treatment costs around $1,000/month, with insurance coverage depending on medical codes. Zepbound is the only FDA-approved GLP-1 for moderate to severe OSA in adults with obesity, though others with obesity, diabetes, or cardiovascular risks may qualify.
Source: Healthline
